2Descarries L,Lemay B,Doucet G,et al.Regional and laminar density of the dopamine innervation in adult rat cerebral cortex[J].Neuroscience,1987,21 (3):807-824.
3张朝佑.人体解剖学[M](第2版)[M].北京:人民卫生出版社,1998.241-248.
4Datiche F,Cattarelli M.Catecholamine innervation of the piriform cortex:a tracing and immunohistochemical study in the rat[J].Brain Res,1996,710(1-2):69-78.
5施密特,特夫斯著,王复周,等译.人体生理学[M].第11版.北京:科学出版社,1981.341.
6Doty RL,Singh A,Tetrud J,et al.Lack of major olfactory dysfunction in MPTP-induced parkinsonism[J].Ann Neurol,1992,32(1):97-100.
7Stern MB,Doty RL,Dotti M,et al.Olfactory function in Parkinson's disease subtypes[J].Neurology,1994,44 (2):266-268.
1[1]CHALON S, EMOND P, BODARD S, et al.Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease[J].Synapse,1999,31(2):134-139.
2[2]BAULIEU J L, RIBERIRO M J, LEVILION-PRUNIER C, et al. Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using 123I-iodolisuride SPECT[J]. Nucl Med Commun,1999,20(1):77-84.
3[3]PRUNIER C, TRANQUART F, COTTIER J P, et al.Quantitative analysis of striatal dopamine D2 receptors with 123I-iodolisuride SPECT in degenerative extrapyramidal diseases[J]. Nucl Med Commun,2001,22(11):1207-1214.
4[4]TORIZUKA K, MIZUNO Y, KUBO A, et al. Phase 2 clinical study of 123I-IBF, a dopamine D2 receptor imaging agent, to evaluate clinical efficacy and safety in Parkinson's disease and Parkinson syndromes[J]. Kaku Igaku,1999,36(8):845-864.
5[5]PIRKER W, ASENBAUM S, WENGER S,et al. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease[J].J Nucl Med, 1997,38(11):1711-1717.
6[6]BERGSTROM K A, YU M, KUIKKA J T,et al. Metabolism of 123I epidepride may affect brain dopamine D2 receptor imaging with single-photon emission tomography[J]. Eur J Nucl Med,2000,27(2):206-208.
7[7]OYANAGI C, KATSUMI Y, HANAKAWA T, et al.Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodoben zofuran single-photon-emission-computed-tomography[J].J Neuroimaging,2002,12(4):316-324.
8[8]GIOBBE D, CASTELLANO G C, PODIO V. Dopamine D2 receptor imaging with SPECT using IBZM in 16 patients with Parkinson disease[J]. Ital J Neurol Sci,1993,14(2):165-169.
9[9]LAULUMAA V, KUIKKA J T, SOININEN H, et al.Imaging of D2 dopamine receptors of patients with Parkinson's disease using single photon emission computed tomography and iodobenzamide I 123[J].Arch Neurol,1993,50(5):509-512.
10[10]WENNING G K,DONNEMILLER E, GRANATA R,et al. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease[J].Mov Disord 1998,13(3):438-445.
7Braak H, Ghebremedhin E, Riib U, et al. Stages in the development of Parkinson's disease-related pathology[J]. Cell Tissue Res,2004,318(1) :121-134.
8Filippi L, Manni C, Pierantozzi M, et al. 123I-FP-CIT semi- quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms[J]. Nucl Med Commun,2005,26(5) :421-426.
9Markesbery WR,Jieha GA, Liu H, et al. Lewy body pathology in normal elderly subjects [J]. Neuropathol Exp Neurol, 2009,68 (7) :816-822.
10Becker G, Mtiller A, Braune S, et al. Early diagnosis of Parkinsoffs disease[J]. J Neurol,2002,249 (Suppl 3) :40-48.
